Women's Health Has Entered Its Era of Scale. Is Commercialization Ready?

Capital is accelerating. The next challenge is turning it into commercial scale.

Women’s health has entered a new phase of growth. More capital, larger rounds, and expanding markets are creating unprecedented opportunity—but funding alone doesn’t build scalable businesses. This article explores the commercial capabilities that must mature alongside innovation to turn investment into adoption, revenue, and durable growth.

By Julie Spence, Founder + Principal

Capital Changes the Question

Women’s health is entering a new phase of growth. More companies are being funded. Rounds are getting larger. Categories are expanding. And innovations that spent years fighting for recognition are increasingly being asked to prove something different: that they can scale.

I've spent more than 30 years inside healthcare commercialization, working across product marketing, enterprise sales, and go-to-market. I've seen what happens as companies move from proving an innovation to building a business around it. The questions change. The decisions become more consequential. And the commercial complexity increases quickly.

Early on, the question is often: Is there a market for this?

As companies grow, the questions become: Which market should we prioritize? Who is the buyer? What evidence will drive adoption? How should we position the product? What should we charge? Which channels will create the strongest path to growth? And where should we place our bets?

Capital gives companies the ability to move faster. But it also raises the stakes on getting those decisions right.

That is why I believe the next phase of women’s health will require more than investment and innovation. It will require the commercial capabilities to turn market opportunity into adoption, revenue, and repeatable growth.

The Era of Scale will require an Era of Commercialization.

Market Clarity: Give the Market a Story It Can Understand

Every company tells a story about itself. The more important question is whether it's the story the market needs to understand.

This becomes harder as companies grow. Products multiply. Buyer groups expand. New markets open. Acquisitions add capabilities. Competitors reposition. Customer priorities change. A company that entered the market solving one problem may now solve five, yet the story the market associates with it may still reflect the company it was several years ago.

Strategic narrative closes that gap.

A strong strategic narrative connects what's changing in the market with what the company is building and why it matters. It provides context for the customer problem, establishes a point of view about where the market is going, clarifies the company's position within that change, and makes the case for why its approach matters now.

This is why strategic narrative is bigger than messaging. Messaging determines how you communicate. Strategic narrative establishes the meaning behind what you communicate.

Buyers aren't simply evaluating features and capabilities. They're deciding whether a problem deserves attention, whether the status quo is still acceptable, whether a different approach is necessary, whether your company is credible, and whether acting now is worth the investment, disruption, and risk.

The clearer that story becomes, the easier it becomes for the market to understand where you fit and why you matter.

Strategic narrative determines the story you need the market to believe.

But understanding the story is only the first step. The organization has to be able to carry it.

Related: When Does Strategic Narrative Become a Commercial Capability?

Commercialization: Build the Capabilities to Carry the Growth

Capital creates opportunity. Commercialization determines how effectively a company turns that opportunity into growth.

This becomes increasingly important as women’s health companies move beyond early validation. A company that began with a single product, customer, or channel may suddenly be considering employers, payers, health systems, providers, consumers, or strategic partners. New funding creates the ability to pursue more of those opportunities—but pursuing everything at once rarely creates scale.

Commercialization creates the discipline to make those choices.

It connects market opportunity to decisions about where to compete, who to serve, how to create value, and how to win. That means understanding the market and buyer, defining the value proposition, establishing positioning, building the evidence required for adoption, determining pricing and packaging, selecting channels, enabling sales, and creating a go-to-market model capable of producing repeatable growth.

These capabilities are interconnected. A weak understanding of the buyer affects positioning. Unclear positioning makes sales harder. The wrong pricing model can slow adoption. Insufficient evidence can stall enterprise decisions. Poor channel sequencing can consume capital without creating meaningful traction.

This is why commercialization is bigger than go-to-market. Go-to-market determines how a company takes an offering to market. Commercialization determines whether the market, product, buyer, value proposition, evidence, economics, and growth model fit together well enough to build a scalable business.

As investment in women’s health increases, that distinction becomes increasingly important. More capital creates more options. More options create more complexity. And more complexity makes commercial judgment more valuable.

Capital gives companies the resources to scale. Commercialization determines where—and how—to deploy them.

But before companies can build repeatable growth, they need to understand what changes as they move from proving an innovation to scaling a business.

Market Conviction: Give People Reasons to Believe

Companies spend a tremendous amount of time determining what they want the market to know about them. Positioning gets refined. Messaging gets approved. Websites get rewritten. Sales teams get enabled. Campaigns go live.

But companies don't get to declare their market position into existence.

The market decides what it believes.

That distinction is why I believe editorial storytelling deserves a much more strategic role in go-to-market.

If your narrative says the market is changing, show the evidence. If you're asking buyers to reconsider how they think about a problem, help them understand why. If you're introducing a new category, contribute to the conversation that makes the category relevant. If you're promising better outcomes, bring forward the customers and evidence that substantiate the claim. If you're taking a position on where healthcare is going, develop a perspective worth following.

Original research, customer evidence, executive perspectives, market analysis, interviews, industry reports, thought leadership, conference conversations, podcasts, video, and media all become ways of building evidence around the narrative.

This is different from creating content to fill an editorial calendar. The starting question isn't, What should we publish?

It's, What does the market need to understand and believe, and what evidence, perspectives, and stories will give people reasons to believe it?

Over time, those stories accumulate. Evidence builds credibility. Customer experience creates proof. Executive perspective demonstrates expertise. Research gives a market argument substance. Consistent participation in an industry conversation creates familiarity and authority.

The company stops simply repeating what it wants the market to believe and starts demonstrating why the belief is warranted.

That's market conviction.

Editorial storytelling gives the market reasons to believe the story.

Commercial Readiness: Build the Business Behind the Innovation

Women’s health has no shortage of innovation. The next challenge is building the commercial infrastructure capable of carrying that innovation into the market at scale.

A company can have compelling science, a meaningful unmet need, enthusiastic early customers, and significant investor backing—and still struggle to create repeatable growth.

Innovation creates the opportunity. Commercial readiness determines whether the business can capture it.

That distinction becomes more important as companies grow.

Early traction may come from founder relationships, early adopters, pilot programs, waitlists, or a small number of highly motivated customers. Those signals matter. But scale requires something more systematic: a clearly defined market, prioritized buyers, a differentiated value proposition, evidence that supports the buying decision, viable economics, the right channels, and a commercial model that can repeatedly acquire, convert, retain, and expand customers.

And in women’s health, that path can become particularly complex.

The same innovation may have relevance to consumers, providers, employers, health systems, and payers—each with different problems, buying criteria, evidence requirements, economics, and paths to adoption. A promising DTC proposition does not automatically translate into an enterprise value proposition. Provider enthusiasm does not necessarily establish payer value. Clinical efficacy alone may not answer the economic questions required for broader adoption.

Commercial readiness means understanding those differences and deliberately building the capabilities required for the next stage of growth.

The starting question isn't simply, How do we sell more?

It's, What has to be true for this business to scale?

That question changes how companies think about market strategy, evidence, pricing, positioning, channels, partnerships, sales, adoption, and expansion. Instead of treating each as a separate activity, they become parts of an interconnected commercial system.

When those pieces mature alongside the innovation, capital can accelerate something that is already becoming repeatable.

When they don't, capital can simply accelerate the search for what works.

The question isn't whether women’s health innovation is ready to scale. It's whether the businesses being built around it are ready to scale with it.

The Market Talks Back

The model doesn't end once the narrative reaches the market. In fact, that's where some of the most valuable information begins to emerge.

Sales conversations reveal where buyers lean in and where they hesitate. Customers expose which outcomes matter most. Competitive activity shows how the market is shifting. Editorial engagement reveals which ideas are resonating. New research changes what can be proven. Products evolve, buyer priorities move, and entirely new conversations emerge.

Those are market signals, and they should continually inform the narrative.

This is why maintaining a strategic narrative is just as important as creating one. A narrative that accurately reflected the market two years ago may no longer create the same urgency or differentiation today. Likewise, the story that helped a company reach one stage of growth may not be sufficient for the next.

The strongest commercial systems listen as well as they communicate. Market intelligence informs the narrative. Product marketing translates changes across the GTM organization. Editorial storytelling tests, substantiates, and advances the conversation. What the market tells you feeds back into what comes next.

The system keeps moving because the market keeps moving.

The Commercialization Gap: Where Promising Companies Can Stall

The gap often appears somewhere between early market validation and repeatable commercial growth.

A company has raised capital. The product is working. Customers are interested. Early traction is encouraging. The market opportunity appears significant. From the outside, the company looks ready to scale.

But internally, many of the decisions required for scale are still being worked out.

The ideal customer may not be fully defined. The buyer and user may be different people. Positioning may still reflect the original product rather than the broader platform the company is becoming. Pricing may have been established before the economic value was fully understood. Sales may be learning the buyer conversation deal by deal. Evidence may demonstrate clinical value without yet answering the questions enterprise buyers need answered.

None of these issues necessarily indicate that something is wrong.

They often indicate that the company has reached a different stage of commercialization.

What worked to establish product-market fit is not always what is required to build a repeatable commercial model. Founder-led selling has to become institutional knowledge. Early customer enthusiasm has to become a defined value proposition. Individual wins have to reveal patterns. Market opportunity has to become market prioritization. And experimentation has to begin producing a system the organization can execute repeatedly.

This is where commercial infrastructure starts to matter.

Market intelligence informs where to compete. Buyer insight sharpens the value proposition. Positioning creates differentiation. Evidence supports adoption. Pricing captures value. Product marketing connects product and market. Sales enablement translates strategy into buyer conversations. Go-to-market aligns those capabilities around a common path to growth.

The goal isn't to add more commercial activity.

It's to make the commercial model more intentional, more connected, and more repeatable.

Scale begins when commercial success stops being episodic and starts becoming repeatable.

The Era of Scale Requires an Era of Commercialization

The growth of investment in women’s health is an important signal. It reflects years of work by founders, researchers, clinicians, investors, advocates, and patients to demonstrate the size of the unmet need—and the opportunity to build better solutions around it.

Now the opportunity is changing.

As more companies move from innovation to growth, the challenge will increasingly be less about proving that women’s health deserves investment and more about building businesses capable of turning that investment into sustained market impact.

That means commercialization has to mature alongside the sector.

The strongest companies won't simply be the ones with the most compelling innovations. They will be the ones that understand their markets deeply, make disciplined choices about where to compete, build compelling value for the buyers who matter, create the evidence required for adoption, and develop commercial models capable of producing repeatable growth.

This isn't a shift away from innovation.

It's what allows innovation to reach more people.

Women’s health has spent decades building the case for greater attention, better solutions, and more investment. The arrival of meaningful capital is a milestone worth celebrating.

But capital is an accelerant. What it accelerates depends on what has been built around it.

Women’s health has entered its Era of Scale. Now it's time to build the commercial infrastructure to match.